This clinical trial focuses on Idiopathic Hypersomnia, a sleep disorder characterized by excessive daytime sleepiness without a known cause. The study will test a new medication called ALKS 2680, which is taken as oral tablets, compared to a placebo. The main goal is to evaluate how well ALKS 2680 works in treating excessive daytime sleepiness in people with Idiopathic Hypersomnia.

The study will last 8 weeks and will test different doses of ALKS 2680. During the study, participants will receive either ALKS 2680 tablets or matching placebo tablets. The medication doses being tested range from 10 to 18 milligrams per day. The study is designed as a double-blind trial, which means neither the participants nor the doctors conducting the study will know who receives which treatment.

The effectiveness of the treatment will be measured by tracking changes in sleepiness levels using standardized assessment tools. Throughout the study, participants’ health and safety will be closely monitored through various medical checks. The study will also look at how well participants tolerate the medication and any effects it may have on their daily functioning.